Epigenetic mechanisms involved in cisplatin-induced nephrotoxicity: An update
Author
dc.contributor.author
Loren, Pía
Author
dc.contributor.author
Saavedra, Nicolás
Author
dc.contributor.author
Saavedra, Kathleen
Author
dc.contributor.author
Zambrano Coloma, Tomas Andrés
Author
dc.contributor.author
Moriel, Patricia
Author
dc.contributor.author
Salazar, Luis A.
Admission date
dc.date.accessioned
2021-11-05T14:07:34Z
Available date
dc.date.available
2021-11-05T14:07:34Z
Publication date
dc.date.issued
2021
Cita de ítem
dc.identifier.citation
Pharmaceuticals 2021, 14, 491.
es_ES
Identifier
dc.identifier.other
10.3390/ph14060491
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/182611
Abstract
dc.description.abstract
Cisplatin is an antineoplastic drug used for the treatment of many solid tumors. Among its
various side effects, nephrotoxicity is the most detrimental. In recent years, epigenetic regulation
has emerged as a modulatory mechanism of cisplatin-induced nephrotoxicity, involving non-coding
RNAs, DNA methylation and histone modifications. These epigenetic marks alter different signaling
pathways leading to damage and cell death. In this review, we describe how different epigenetic
modifications alter different pathways leading to cell death by apoptosis, autophagy, necroptosis,
among others. The study of epigenetic regulation is still under development, and much research
remains to fully determine the epigenetic mechanisms underlying cell death, which will allow leading
new strategies for the diagnosis and therapy of this disease.
es_ES
Patrocinador
dc.description.sponsorship
ANID-FAPESP 19/13250-1
Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)
CONICYT FONDECYT 1171765
Programa de Formacion de Investigadores Postdoctorales, VRIP, Universidad de La Frontera, Temuco, Chile VRIP 21001
es_ES
Lenguage
dc.language.iso
en
es_ES
Publisher
dc.publisher
MDPI
es_ES
Type of license
dc.rights
Attribution-NonCommercial-NoDerivs 3.0 United States